Lantern Pharma Raises $4.4M to Fuel AI-Driven Oncology Pipeline

Lantern Pharma (NASDAQ: LTRN), a clinical-stage precision oncology company, has closed a registered direct offering that raised approximately $4.4 million in gross proceeds. The offering involved the sale of 2,135,923 shares of common stock (or pre-funded warrants) at $2.06 per share, along with a concurrent private placement of unregistered warrants to purchase up to an equal number of shares at $2.27 per share. If fully exercised, these warrants could generate an additional $4.85 million, bolstering the company's financial runway.

Lantern Pharma is at the forefront of integrating artificial intelligence into oncology drug development. Its proprietary RADR(R) platform leverages AI and machine learning to streamline the discovery and development of cancer therapies. The company's clinical pipeline includes promising candidates such as LP-184 (acylfulvene) and LP-284 (a TC-NER targeting compound for hematologic and solid tumors), as well as LP-300, which is being evaluated in the HARMONIC Phase 2 trial for never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. Through its wholly owned subsidiary Starlight Therapeutics, Lantern is also developing LP-184 for pediatric CNS cancers. Additionally, Lantern's multi-agentic AI co-scientist platform, withZeta.ai, is now commercially available as a subscription-based research platform for the global biomedical community, representing a new revenue stream. The company operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas.

This capital raise comes at a critical time as Lantern advances its clinical trials and expands its AI-driven initiatives. The proceeds from the offering are expected to support the ongoing development of its pipeline and the commercialization of withZeta.ai. For investors, the news highlights Lantern's commitment to leveraging cutting-edge technology to address unmet needs in oncology. The company's use of AI to accelerate drug development could reduce costs and timelines, potentially bringing new therapies to patients faster. As Lantern continues to progress, its innovative approach may set a precedent for precision oncology and AI in drug discovery.